KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xenon Pharmaceuticals (XENE) EBITDA: 2012-2024

Historic EBITDA for Xenon Pharmaceuticals (XENE) over the last 13 years, with Dec 2024 value amounting to -$279.3 million.

  • Xenon Pharmaceuticals' EBITDA fell 52.82% to -$90.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$316.0 million, marking a year-over-year decrease of 43.05%. This contributed to the annual value of -$279.3 million for FY2024, which is 30.48% down from last year.
  • Per Xenon Pharmaceuticals' latest filing, its EBITDA stood at -$279.3 million for FY2024, which was down 30.48% from -$214.1 million recorded in FY2023.
  • Xenon Pharmaceuticals' EBITDA's 5-year high stood at -$31.3 million during FY2020, with a 5-year trough of -$279.3 million in FY2024.
  • Moreover, its 3-year median value for EBITDA was -$214.1 million (2023), whereas its average is -$207.5 million.
  • Per our database at Business Quant, Xenon Pharmaceuticals' EBITDA rose by 26.90% in 2020 and then plummeted by 152.37% in 2021.
  • Xenon Pharmaceuticals' EBITDA (Yearly) stood at -$31.3 million in 2020, then plummeted by 152.37% to -$79.0 million in 2021, then plummeted by 63.49% to -$129.1 million in 2022, then crashed by 65.75% to -$214.1 million in 2023, then tumbled by 30.48% to -$279.3 million in 2024.